Soligenix Profile

USD 0.01  0.65%

Acquisition by Jerome Zeldis of 40541 shares of Soligenix subject to Rule 16b-3

Soligenix insider trading alert for grant of stock option (right to buy) by Jerome Zeldis, the corporate stakeholder, on May 28, 2018. This event was filed by Soligenix Inc with SEC on 2016-06-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Soligenix Summary

Soligenix (SNGX) is traded on Nasdaq Capital Markets in USA. It is located in NEW JERSEY, U.S.A and employs 18 people. Soligenix was previously known as Soligenix and was traded on Nasdaq Capital Markets under the symbol SNGX. Soligenix is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 13.91 M. Soligenix conducts business under Healthcare sector and is part of Biotechnology industry. This company has 8.75 M outstanding shares of which 342.33 K shares are at this time shorted by private and institutional investors with about 10.54 trading days to cover. SOLIGENIX currently holds about 6.37 M in cash with (6.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check Soligenix Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 1.54HorizonTargetOdds Above 1.54
25.45%30 days 1.54 74.27%
Based on normal probability distribution, the odds of Soligenix to move above current price in 30 days from now is about 74.27% (This Soligenix probability density function shows the probability of Soligenix Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Knoll Capital Management LpCommon Shares837.8 K1.6 M
Vanguard Group IncCommon Shares222.4 K434 K
Cvi Holdings LlcWarrants61 K35 K
View Soligenix Diagnostics

Selected Soligenix Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Soligenix Against Markets

Similar Equity Warning - SNGX

Soligenix was forked
  The entity Soligenix with a symbol SNGX was recently forked. You can potentially use Soligenix with a symbol SNGX from now on.
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Soligenix are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 18 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Chairman, CEO and PresChristopher SchaberView All
Thematic Classification
Currently Active Investing Idea
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
Business Address29 Emmons Drive
ExchangeNasdaq Capital Markets
Prior SymbolSNGX
New SymbolSNGX
Contact Number609 538 8200
Related EntitySNGXD
CurrencyUSD - US Dollar

Diversify with Soligenix

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Soligenix to your portfolio


Soligenix Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.85March 23, 2017
Soligenix normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Soligenix Corporate Directors
Jerome Zeldis Independent Director
Marco Brughera Director
Gregg Lapointe Independent Director
Also please take a look at World Market Map. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.